Yang H - Search Results

1

Biomarker-guided targeted and immunotherapies in malignant pleural mesothelioma.

Yang H, Xu D, Schmid RA, Peng RW. Yang H, et al. Ther Adv Med Oncol. 2020 Nov 12;12:1758835920971421. doi: 10.1177/1758835920971421. eCollection 2020. Ther Adv Med Oncol. 2020. PMID: 33240401 Free PMC article. Review.

2

Increased sensitivity to apoptosis upon endoplasmic reticulum stress-induced activation of the unfolded protein response in chemotherapy-resistant malignant pleural mesothelioma.

Xu D, Liang SQ, Yang H, Lüthi U, Riether C, Berezowska S, Marti TM, Hall SRR, Bruggmann R, Kocher GJ, Schmid RA, Peng RW. Xu D, et al. Among authors: yang h. Br J Cancer. 2018 Jul;119(1):65-75. doi: 10.1038/s41416-018-0145-3. Epub 2018 Jun 20. Br J Cancer. 2018. PMID: 29921948 Free PMC article.

3

mTOR mediates a mechanism of resistance to chemotherapy and defines a rational combination strategy to treat KRAS-mutant lung cancer.

Liang SQ, Bührer ED, Berezowska S, Marti TM, Xu D, Froment L, Yang H, Hall SRR, Vassella E, Yang Z, Kocher GJ, Amrein MA, Riether C, Ochsenbein AF, Schmid RA, Peng RW. Liang SQ, et al. Among authors: yang h, yang z. Oncogene. 2019 Jan;38(5):622-636. doi: 10.1038/s41388-018-0479-6. Epub 2018 Aug 31. Oncogene. 2019. PMID: 30171261

4

HSP90/AXL/eIF4E-regulated unfolded protein response as an acquired vulnerability in drug-resistant KRAS-mutant lung cancer.

Yang H, Liang SQ, Xu D, Yang Z, Marti TM, Gao Y, Kocher GJ, Zhao H, Schmid RA, Peng RW. Yang H, et al. Among authors: yang z. Oncogenesis. 2019 Aug 20;8(9):45. doi: 10.1038/s41389-019-0158-7. Oncogenesis. 2019. PMID: 31431614 Free PMC article.

5

Endoplasmic Reticulum Stress Signaling as a Therapeutic Target in Malignant Pleural Mesothelioma.

Xu D, Yang H, Yang Z, Berezowska S, Gao Y, Liang SQ, Marti TM, Hall SRR, Dorn P, Kocher GJ, Schmid RA, Peng RW. Xu D, et al. Among authors: yang h, yang z. Cancers (Basel). 2019 Oct 8;11(10):1502. doi: 10.3390/cancers11101502. Cancers (Basel). 2019. PMID: 31597321 Free PMC article.

6

New Horizons in KRAS-Mutant Lung Cancer: Dawn After Darkness.

Yang H, Liang SQ, Schmid RA, Peng RW. Yang H, et al. Front Oncol. 2019 Sep 25;9:953. doi: 10.3389/fonc.2019.00953. eCollection 2019. Front Oncol. 2019. PMID: 31612108 Free PMC article. Review.

7

CRISPR Screening Identifies WEE1 as a Combination Target for Standard Chemotherapy in Malignant Pleural Mesothelioma.

Xu D, Liang SQ, Yang H, Bruggmann R, Berezowska S, Yang Z, Marti TM, Hall SRR, Gao Y, Kocher GJ, Schmid RA, Peng RW. Xu D, et al. Among authors: yang h, yang z. Mol Cancer Ther. 2020 Feb;19(2):661-672. doi: 10.1158/1535-7163.MCT-19-0724. Epub 2019 Nov 6. Mol Cancer Ther. 2020. PMID: 31694888

8

The Association of BAP1 Loss-of-Function With the Defect in Homologous Recombination Repair and Sensitivity to PARP-Targeted Therapy.

Yang H, Xu D, Gao Y, Schmid RA, Peng RW. Yang H, et al. J Thorac Oncol. 2020 Jun;15(6):e88-e90. doi: 10.1016/j.jtho.2020.02.028. J Thorac Oncol. 2020. PMID: 32471567 Free article. No abstract available.

9

Oncolytic Viral Therapy for Malignant Pleural Mesothelioma.

Yang H, Xu D, Gao Y, Schmid RA, Peng RW. Yang H, et al. J Thorac Oncol. 2020 Jul;15(7):e111-e113. doi: 10.1016/j.jtho.2020.03.007. J Thorac Oncol. 2020. PMID: 32593447 Free article. No abstract available.

10

Systematic Analysis of Aberrant Biochemical Networks and Potential Drug Vulnerabilities Induced by Tumor Suppressor Loss in Malignant Pleural Mesothelioma.

Yang H, Xu D, Yang Z, Yao F, Zhao H, Schmid RA, Peng RW. Yang H, et al. Among authors: yang z. Cancers (Basel). 2020 Aug 17;12(8):2310. doi: 10.3390/cancers12082310. Cancers (Basel). 2020. PMID: 32824422 Free PMC article.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

56,627 results

Search Page